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1 Analysis of the P2Y family of nucleotide-activated G-protein-coupled receptors has been
compromised by the lack of selective high-affinity, high-specific-radioactivity radioligands. We have
pursued quantification of the P2Y1 receptor through the development of a series of selective P2Y1
receptor antagonists.
2 Recently, we synthesized 2-iodo-N6-methyl-(N)-methanocarba-20-deoxyadenosine 30,50-bisphos-
phate (MRS2500), a selective, competitive antagonist that exhibits a Ki of 0.8 nM in competition-
binding assays with [3H]MRS2279. A 30-monophosphate precursor molecule, MRS2608, was
radiolabeled at the 50 position with 32P using polynucleotide kinase and [g32P]ATP to yield
[32P]MRS2500.
3 [32P]MRS2500 bound selectively to Sf9 insect cell membranes expressing the human P2Y1 receptor
(Sf9-P2Y1), but did not detectably bind membranes expressing other P2Y receptors. P2Y1 receptor
binding to [32P]MRS2500 was saturable with a KD of 1.2 nM. Agonists and antagonists of the P2Y1
receptor inhibited [32P]MRS2500 binding in Sf9-P2Y1 membranes with values in agreement with those
observed in functional assays of the P2Y1 receptor.
4 A high-affinity binding site for [32P]MRS2500 (KD¼ 0.33 nM) was identified in rat brain, which
exhibited the pharmacological selectivity of the P2Y1 receptor. Distribution of this binding site varied
among rat tissues, with the highest amount of binding appearing in lung, liver, and brain. Among
brain regions, distribution of the [32P]MRS2500 binding site varied by six-fold, with the highest and
lowest amounts of sites detected in cerebellum and cortex, respectively.
5 Taken together, these data illustrate the synthesis and characterization of a novel P2Y1 receptor
radioligand and its utility for examining P2Y1 receptor expression in native mammalian tissues.
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Introduction
Extracellular nucleotides signal through two classes of
membrane-bound receptors to mediate a multiplicity of
intracellular responses. The P2X receptors are ligand-gated
ion channels and are primarily activated by ATP. The P2Y
receptors are seven-transmembrane-spanning G-protein-
coupled receptors, and are activated by adenine and uridine
nucleotides. The P2Y receptor family consists of eight
members that can be subclassified based on selectivity of G
protein coupling and sequence homology. P2Y1, P2Y2, P2Y4,
P2Y6, and P2Y11 receptors couple to the Gaq class of guanine
nucleotide-binding proteins, which signal downstream to
trigger inositol lipid hydrolysis and subsequent mobilization
of intracellular calcium. The P2Y11 receptor also couples to the
Gas family of G proteins to stimulate adenylyl cyclase. The
P2Y12, P2Y13, and P2Y14 receptors exhibit high sequence
homology and couple to the Gai family of G proteins,
resulting in inhibition of adenylyl cyclase activity (Burnstock,
1996; Burnstock & Knight, 2004).
The P2Y1 receptor is preferentially activated by ADP, while
ATP is a weak partial agonist, and UTP and UDP are inactive
(Schachter et al., 1996; Leon et al., 1997; Palmer et al., 1998).
This receptor plays an essential role in ADP-promoted platelet
aggregation by triggering shape change and an initial,
reversible phase of aggregation (Jantzen et al., 1999). P2Y1
receptor mRNA has been detected in numerous tissues
(Janssens et al., 1996; Leon et al., 1996); however, a direct
study of this receptor and its related physiology historically
has been difficult due to the lack of a reliable radioligand-
binding assay.
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We have developed a series of competitive antagonists
that selectively inhibit P2Y1 receptor-promoted signaling.
Adenosine derivatives with phosphate groups at the 50 and
20 or 30 positions of the ribose ring were initially identified
as selective, competitive antagonists (Boyer et al., 1996).
Structure–activity studies for adenosine bisphosphate deriva-
tives substituted at various positions of the adenine and ribose
rings along with molecular modeling and site-directed muta-
genesis have led to the development of non-nucleotide-
antagonists that are highly selective for the P2Y1 receptor,
exhibit low nanomolar potency for inhibiting downstream
receptor signaling, and display limited susceptibility to
metabolism by surface-localized nucleotide hydrolyzing
enzymes (Jiang et al., 1997; Boyer et al., 1998; 2002; Camaioni
et al., 1998; Moro et al., 1998; Nandanan et al., 1999; 2000;
Kim et al., 2000; 2001; 2002). One of these molecules, 2-chloro-
N6-methyl-(N)-methanocarba-20-deoxyadenosine-30,50-bisphos-
phate ([3H]MRS2279), was developed into an antagonist
radioligand for the P2Y1 receptor by a multi-step radio-
synthetic scheme (Waldo et al., 2002). While the development
of a radioligand-binding assay using this molecule provides a
reliable tool for quantification of recombinant P2Y1 receptors
and screening of new P2Y1 receptor ligands, its low specific
activity (89Cimmol1) and intermediate affinity for the P2Y1
receptor (KD: 8 nM) limit its general application for broadly
quantifying P2Y1 receptors in native mammalian tissues.
Recently, 2-iodo-N6-methyl-(N)-methanocarba-20-deoxyade-
nosine-30,50-bisphosphate (MRS2500) was synthesized as a com-
petitive P2Y1 receptor antagonist that inhibited [
3H]MRS2279
binding with an affinity (Ki¼ 0.79 nM) 10 times greater than
MRS2279 (Kim et al., 2003). We have chosen this molecule as
a template to develop a higher-affinity, high-specific-
radioactivity antagonist radioligand for the P2Y1 receptor.
MRS2500 was synthesized in radioactive form by the facile,
single-step kinase-catalyzed phosphorylation of a precursor
molecule to yield [32P]MRS2500 with a theoretical specific
activity of 9120Cimmol1. In this study, we describe the
synthesis of this novel radioligand, the development of a high-
specific-activity radioligand-binding assay for the P2Y1
receptor, and the quantification of P2Y1 receptors in various
tissues of the adult rat.
Methods
Animals
Adult male Harlan Sprague–Dawley rats weighing 300–400 g
were group housed and maintained on a 12 : 12 h light : dark
cycle with access to food and water ad libitum. Animals were
killed by decapitation by a trained laboratory animal
technician. All procedures were carried out in accordance with
the guidelines of the University of North Carolina Institutional
Animal Care and Use Committee.
Precursor for synthesis of MRS2500
The general synthetic approach for 2-iodo-N6-methyl-(N)-
methanocarba-20-deoxyadenosine-30-monophosphate, MRS2608,
a precursor of MRS2500, was described (Kim et al., 2003). The
detailed synthesis will be published separately.
Enzymatic synthesis of [32P]MRS2500 from MRS2608
MRS2608 (50 nmol, 5ml of a 10mM solution in Tris, pH 7.5)
was combined with 1.5 ml of 10 reaction buffer (500mM Tris-
HCl, 100mM MgCl2, 50mM dithiothreitol, 1mM spermidine,
and 1mM EDTA, pH 7.5), 1mCi of [g32P]ATP
(7 ml, 0.16 nmol, 150mCiml1), and 2ml (20U) of 30-phospha-
tase-free polynucleotide kinase. The sample was mixed by
pipetting and the kinase-catalyzed reaction was incubated
at 371C for 1 h. The entire reaction volume was then injected
onto a Luna 5m C18(2) column (4.6 250mm) at a flow rate
of 1mlmin1 in a mobile phase of 5% acetonitrile/95% 0.1M
triethylammonium acetate (5% A/95% B). The column was
washed for 30min in 5% A/95% B to remove free [g32P]ATP,
and [32P]MRS2500 was eluted using a linear gradient of 5%
A/95% B to 60% A/40% B over 50min. [32P]MRS2500 eluted
at 48min, that is, 18min after the start of the gradient
(approximately 75% A/25% B). The precursor molecule,
MRS2608, which was detected by UV (275 nM) eluted at
50min. Fractions of 1ml were collected during purification,
and radioactivity in each fraction was quantified by liquid
scintillation counting of a 5ml aliquot of each fraction.
[32P]MRS2500 has been purified by this procedure approxi-
mately 10 times, with a typical yield of approximately 20%.
[32P]MRS2500 was stored at 201C until use.
P2Y1 receptor expression in Sf9 insect cells
Sf9 insect cell membranes expressing recombinant P2Y
receptors were prepared as described in detail previously
(Waldo et al., 2002). Briefly, recombinant baculoviruses
encoding epitope-tagged constructs of the human P2Y1,
P2Y2, or P2Y12 receptors, or an avian P2Y receptor (Boyer
et al., 1997) were constructed using established protocols.
Suspension cultures of Sf9 cells were infected with recombi-
nant baculoviruses, and plasma membranes were prepared
from uninfected (wild type) or infected cells after cell lysis and
high-speed centrifugation. The membranes were frozen in
aliquots at 801C.
Preparation of membranes from rat tissues
Adult male Harlan Sprague–Dawley rats were killed and
organs were harvested and placed in 5ml homogenization
buffer (20mM Hepes, pH 7.5, 145mM NaCl, 5mM MgCl2) per
gram wet weight tissue. Whole organs or combined brain
regions from groups of 2–6 rats were homogenized with a
Polytron tissue disrupter for 45–60 s. Homogenized samples
were centrifuged at 35,000 g for 10min. The resulting pellets
were resuspended in 3ml homogenization buffer per gram wet
weight tissue and centrifugation was repeated two times. Final
resuspensions were in homogenization buffer plus 5% glycerol
and the samples were stored at 801C. Protein concentrations
were determined using the BCA protein assay.
Radioligand-binding assay
Membranes were typically incubated with 0.1–0.25 nM
[32P]MRS2500 in assay buffer (20mM Hepes, 145mM NaCl,
5mM MgCl2, pH 7.5) in a 25ml reaction volume in
12 75mm2 conical polypropylene tubes. Saturation-binding
isotherms were generated at concentrations of [32P]MRS2500
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ranging from 0.01 to 6 nM in a total volume of 20 ml.
Incubations were from 15 to 45min in an ice-water bath and
were terminated by the addition of 3.5ml of ice-cold assay
buffer followed by vacuum filtration over Whatman GF/A
glass microfiber filters. The filters were washed with 7ml ice
cold assay buffer and radioactivity on each filter was
quantified by liquid scintillation counting. Specific binding
was defined as total [32P]MRS2500 bound minus binding
occurring in the presence of 10 or 100 mM MRS2179.
Materials
30-phosphatase-free polynucleotide kinase was from Roche
Diagnostics Corp., Indianapolis, IN, U.S.A. MRS2179 was
from Tocris-Cookson, Inc., Ellisville, MO, U.S.A. [g32P]ATP
was from Perkin-Elmer, Inc., Boston, MA, U.S.A. All other
drugs were from Sigma-Aldrich Corp., St Louis, MO, U.S.A.
The Luna 5m C18(2) HPLC column was from Phenomenex,
Inc., Torrence, CA, U.S.A.
Data analysis
All experiments were carried out in duplicate or triplicate
assays and were carried out at least three times or on samples
from three individual animals. Data were analyzed using
GraphPad Prism (GraphPad Software, San Diego, CA,
U.S.A.). Data are presented as the mean7s.e.m. from
combined multiple experiments or in some cases as a data set
from a typical experiment.
Results
Structure–activity relationships for a series of synthetic
adenine nucleotide analogs have led to the development of a
class of non-nucleotide adenosine bisphosphate derivatives
that selectively inhibit the P2Y1 receptor (Boyer et al., 1998;
Moro et al., 1998; Nandanan et al., 1999; Kim et al., 2002;
2003). The replacement of the ribose ring of adenosine 30,50-
bisphosphate with a Northern-constrained cyclopentane struc-
ture and other modifications of the adenine base, including
an N6-methyl addition, have yielded molecules that are
highly selective for P2Y1 over other P2Y, P2X, and adenosine
receptors. These non-nucleotide molecules are also presumed
to circumvent the problem of nonspecific binding to the
large number of other nucleotide-binding proteins present in
mammalian cells. Recently, one of these molecules MRS2500,
was found to interact with the P2Y1 receptor with subnano-
molar affinity. This molecule was selected as the template for
development of a high-specific-activity, 32P-labeled radioligand
to quantify endogenous P2Y1 receptors in mammalian tissues.
Synthesis of [32P]MRS2500
MRS2500 inhibited binding of the P2Y1 receptor radioligand
[3H]MRS2279 with a Ki value of 0.79 nM, and inhibited
2MeSADP-promoted inositol phosphate accumulation with a
calculated KB value of 1.74 nM (Kim et al., 2003). A precursor
to MRS2500 was generated with the goal of synthesizing a
high-specific-activity radioligand. The precursor molecule,
MRS2608, contains a phosphate group at the 30-position and
a hydroxyl group at the 50-position, which potentially allows
phosphorylation by polynucleotide kinase using [g32P]ATP as
the 50-phosphate donor.
Reaction conditions for polynucleotide kinase-catalyzed
radiophosphorylation were optimized using unlabeled ATP
and adenosine-30-monophosphate (A30MP) as the phosphate
acceptor. The extent of phosphorylation was quantified using
ion exchange chromatography. Since polynucleotide kinase is
known to exhibit small amounts of 30-phosphatase activity,
reactions were carried out with a mutant form of the enzyme
containing a C-terminal deletion that results in ablation of
its 30-phosphatase activity (Wang & Shuman, 2002). Lack of
30-phosphatase activity was confirmed using A30MP as
substrate (data not shown). A30MP was stable in the presence
of 30-phosphatase-free polynucleotide kinase in the absence
of ATP at 371C for up to 24 h; incubation of A30MP with
unmodified polynucleotide kinase under identical conditions
resulted in the appearance of a small amount of adenosine
(data not shown).
Reaction conditions that resulted in optimal phosphoryla-
tion of A30MP were applied to 32P-phosphorylate MRS2608 to
generate [32P]MRS2500 (Figure 1). Approximately 20% of the
added [32P] radioactivity was routinely recovered in a single
peak that eluted from the reversed-phase column with a
retention time of 48min. The retention time of the radioactive
product corresponded to the retention time of purified,
unlabeled MRS2500 (Kim et al., 2003) under the same mobile
phase conditions. Contamination of purified [32P]MRS2500
with the precursor molecule MRS2608 was less than 1% in
multiple purification procedures.
Selectivity of [32P]MR2500 for the P2Y1 receptor
To determine selectivity of the novel radioligand for the P2Y1
receptor, [32P]MRS2500 binding was evaluated in membranes
from wild-type Sf9 (Sf9-wt) insect cells or Sf9 insect cells
expressing human P2Y1 (Sf9-P2Y1), P2Y2 (Sf9-P2Y2), or P2Y12
(Sf9-P2Y12) receptors or the avian P2Y receptor (Sf9-P2Ya)
(Boyer et al., 1997). As shown in Figure 2, [32P]MRS2500
binding in Sf9-P2Y1 membranes was 15-fold higher than
binding observed in Sf9-wt membranes, and was inhibited by
90% in the presence of the P2Y1-selective antagonist
MRS2179 (10 mM). In contrast, [32P]MRS2500 binding in
Sf9-P2Y2, Sf9-P2Y12, and Sf9-P2Ya membranes was essentially
identical to that observed in Sf9-wt membranes and was not
Figure 1 Synthesis of [32P]MRS2500. MRS2608 (5 ml of a 10mM
solution) was combined with 1.5ml of 10 reaction buffer, 1mCi of
[g32P]ATP (7 ml, 0.16 nmol, 150mCiml1), and 2 ml (20U) of 30-
phosphatase-free polynucleotide kinase. The sample was mixed by
pipetting and incubated at 371C for 1 h. The entire reaction volume
was then injected onto a Luna 5m C18(2) column for purification
under mobile phase conditions as described in Methods.
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affected by MRS2179. These results indicate that
[32P]MRS2500 binds specifically to P2Y1 receptors but not
to other P2Y receptors in Sf9 membranes.
High-affinity binding of [32P]MRS2500 to the P2Y1
receptor
Optimal conditions for radioligand binding were determined in
preliminary experiments. Specific binding occurring at 41C was
at least as great as that observed at room temperature (data
not shown), and therefore all subsequent binding analyses were
carried out at 41C. Time-course experiments revealed rapid
association of [32P]MRS2500 such that steady-state binding
occurred within 2min at 41C. Prebound radioligand disso-
ciated rapidly upon addition of a saturating concentration
of MRS2179 (10 mM), with half of the bound radioligand
dissociating within approximately 90 s.
Saturation-binding analysis was performed to determine the
affinity of [32P]MRS2500 for the recombinant human P2Y1
receptor expressed in Sf9 membranes (Figure 3). Saturation-
binding isotherms exhibited one-site binding kinetics with a KD
of 1.170.35 nM (n¼ 3) and an average Bmax of 4.872.2 pmol
receptormg1 protein in three experiments from a single
membrane preparation.
Pharmacological selectivity of [32P]MRS2500 binding
The capacity of several agonists and antagonists of the P2Y1
receptor and other P2Y receptors to compete with
[32P]MRS2500 for binding was investigated in Sf9-P2Y1
membranes. Owing to the high specific activity of
[32P]MRS2500, competition curves could be generated with
minimal amounts of protein (250–500 ng), limiting the altera-
tion of added nucleotides by membrane-bound nucleotide-
metabolizing enzymes. Agonists known to bind to the P2Y1
receptor inhibited binding of [32P]MRS2500 in a concentra-
tion-dependent manner (Figure 4a). The rank order of potency
observed was 2MeSADP42MeSATP4ADP4ATPgS4
ADPbS4ATP. This order was in agreement with the predicted
potencies for the P2Y1 receptor based on previous observa-
tions of agonist-promoted P2Y1 receptor second-messenger
signaling in cells continuously superfused with drug-containing
medium (Palmer et al., 1998). Moreover, Ki values (Table 1)
were in excellent agreement with values determined in
competition assays with [3H]MRS2279, and the human P2Y1
receptor purified to homogeneity (Waldo & Harden, 2004).
The P2Y1 receptor is known to bind adenine nucleotides
specifically and is not activated by UTP or UDP; accordingly,
uridine nucleotides did not compete with [32P]MRS2500 for
binding to the P2Y1 receptor.
P2Y1 receptor antagonists were also investigated for their
capacity to compete with [32P]MRS2500 for binding to the
P2Y1 receptor. MRS2179, MRS2279 and MRS2500 inhibited
[32P]MRS2500 binding with Ki values in good agreement with
KB values determined for these same antagonists for inhibition
of P2Y1 receptor-promoted second messenger signaling
(Figure 4b, Table 1).
[32P]MRS2500 binding in rat brain
One of the potential advantages of a high-specific-activity
radioligand is high sensitivity for detection of receptors in
native tissues. To determine the utility of [32P]MRS2500 for
detection of P2Y1 receptors in native tissues, membranes were
prepared from brains of adult male Sprague–Dawley rats. As
Figure 2 [32P]MRS2500 binding in Sf9 membranes expressing P2Y
receptors. Wild-type Sf9 membranes or membranes expressing the
human P2Y1, P2Y2, or P2Y12 receptors or the avian P2Y receptor,
P2Ya (10 mg each) were incubated with 220 pM [32P]MRS2500 in
the presence or absence of 10 mM MRS2179 to determine non-
specific binding. Values are reported as total fmol [32P]MRS2500
bound7s.e.m. from a representative experiment (n¼ 3).
Figure 3 Saturation-binding isotherm for [32P]MRS2500 binding
to the human P2Y1 receptor. Sf9-P2Y1 membranes (10mg per assay)
were incubated for 45min with the indicated concentrations of
[32P]MRS2500 without or with the P2Y1R selective antagonist
MRS2179 (10 mM). Values are reported as total fmol [32P]MRS2500
bound7s.e.m. from a representative experiment (n¼ 3). Inset,
Scatchard transformation of the data.
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shown in Figure 5a, saturation-binding analysis revealed
binding of [32P]MRS2500 to a homogenous population of
binding sites in rat brain with high affinity (KD:
0.3370.02 nM). An average Bmax value of 48.978.7 fmol re-
ceptormg1 protein was determined (n¼ 3). To confirm the
identity of this high affinity binding site as the rat P2Y1
receptor, pharmacological selectivity of P2Y1 receptor anta-
gonists was examined. The P2Y1 selective antagonists,
MRS2179, MRS2279, and MRS2500, competed for binding
of [32P]MRS2500 in rat brain membranes with Ki values of
1.9770.74, 27.478.4, and 267772, respectively (n¼ 3). These
values were in agreement with values obtained at the
recombinant human P2Y1 receptor (Table 2). Taken together,
these data demonstrate that [32P]MRS2500 is useful for
quantification of P2Y1 receptors in adult rat brains. Pre-
liminary studies revealed a large amount of breakdown of
nucleotides by brain homogenates; therefore, we have not
pursued agonist competition binding further in these studies of
native P2Y1 receptors.
Tissue distribution of the rat P2Y1 receptor
Having confirmed the utility of [32P]MRS2500 for labeling
P2Y1 receptors in rat brain, we determined the relative
density of P2Y1 receptors in a variety of rat tissues (Figure 6).
Among tissues examined with a submaximal concentration
of [32P]MRS2500 (4 nM), lung, liver, and brain exhibited
the highest relative amounts of specific binding, with
55710, 3173, and 3175 fmol [32P]MRS2500 boundmg1
protein, respectively. Heart, abdominal muscle, spleen, and
stomach exhibited moderate receptor levels. Testes and
kidney bound the least amounts of radioligand, 6.572.4
and 2.771.7 fmol [32P]MRS2500 boundmg1 protein, respec-
tively, and, in some cases, specific binding in these tissues
was undetectable.
P2Y1 receptor distribution in rat brain
P2Y1 receptor mRNA is abundantly expressed in brain, and
this receptor has been implicated in a number of neuronal
physiologies, including regulation of neurotransmission, an-
xiolysis, and protection of astrocytes from oxidative stress-
induced damage (Kittner et al., 2003; Luthardt et al., 2003;
Shinozaki et al., 2005). Saturation-binding analyses were
performed in five major brain regions – cerebellum, cortex,
midbrain, hypothalamus, and, hippocampus. Among the brain
regions examined, cerebellum exhibited the highest number of
binding sites with a Bmax value of 112717 fmol [
32P]MRS2500
bound per mg protein (Table 2). Midbrain, hypothalamus, and
hippocampus displayed intermediate densities of binding sites,
and cortex displayed the lowest number of binding sites with a
Bmax value of 21.772.4 fmol [
32P]MRS2500 bound per mg
Figure 4 Competition of P2Y1 receptor agonists and antagonists with [
32P]MRS2500 for binding to P2Y1 receptor-expressing
Sf9 membranes. (a) Sf9-P2Y1 membranes (250 ng per assay) were incubated with 100 pM [
32P]MRS2500 and the indicated
concentrations of P2Y1 receptor agonists. (b) Sf9-P2Y1 membranes (500 ng per assay) were incubated with 200 pM [
32P]MRS2500
and the indicated concentrations of the P2Y1 receptor selective antagonists. Values are reported as % binding observed in the
absence of competing ligand. Data shown are averages of triplicate samples7s.e.m. from a representative experiment.
Table 1 Ki values for P2Y1 receptor agonists and
antagonists in P2Y1 receptor-expressing Sf9 mem-
branes









MRS2500 3 2.3570.48 1.74 (Kim et al., 2003)
MRS2279 5 46.577.9 8.91 (Boyer et al., 2002)
MRS2179 3 11779 102 (Boyer et al., 1998)
Values reported are the average of three or more experi-
ments7s.e.m.
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protein. Thus, P2Y1 receptor expression varies by approxi-
mately six-fold among the major brain regions examined.
Discussion
Study of the P2Y1 receptor has been significantly advanced by
the development of selective pharmacological tools that
directly target this signaling protein. In this report, we describe
the synthesis and confirm the utility of [32P]MRS2500 as a
novel high-affinity, high-specific-radioactivity antagonist radio-
ligand for the P2Y1 receptor. [
32P]MRS2500 binds selectively
to the human P2Y1 receptor with a KD of 1.2 nM. We have used
this high-affinity radioligand to quantify P2Y1 receptors in a
variety of rat tissues, and among the tissues examined, relative
receptor levels were highest in lung, liver, and brain. We also
examined receptor levels in several major brain regions and
found a six-fold range of expression, with the highest
and lowest densities of receptors found in the cerebellum and
cortex, respectively. To our knowledge, this is the first
unambiguous demonstration of a broadly useful high-speci-
fic-activity radioligand for a P2Y receptor natively expressed
in mammalian tissues. Given the availability of the precursor,
MRS2608, the preparative method is sufficiently simple to
allow its convenient synthesis.
Development of selective P2Y1 receptor antagonists began
with the identification of adenosine bisphosphate molecules as
competitive antagonists. The presence of a 50 phosphate group
and an accompanying 20 or 30 phosphate group on the ribose
moiety allowed recognition of these molecules by the P2Y1
receptor without receptor activation (Boyer et al., 1996).
Removal of the 20 hydroxyl group of the ribose entity
Figure 5 [32P]MRS2500 binding in adult male rat brain. (a) Membranes prepared from adult male rat brain (30 mg per assay) were
incubated for 45min with the indicated concentrations of [32P]MRS2500 without or with the P2Y1R selective antagonist MRS2179
(100 mM). Inset, Scatchard transformation of the data. (b) Membranes from adult male rat brains (50 mg per assay) were incubated
with 200 pM [32P]MRS2500 and the indicated concentrations of the indicated P2Y1 receptor antagonists. Values are reported as %
binding observed in the absence of competing ligand. Data shown are averages of triplicate samples (a) or averages of triplicate
samples7s.e.m. (b) from a representative experiment (n¼ 3).
Table 2 KD and Bmax values for [
32P]MRS2500
binding in rat brain regions
Region KD (nM) Bmax (fmolmg
1 protein)






Values reported are the average of three experiments7s.e.m.
Figure 6 [32]MRS2500 binding in adult rat tissues. Membranes
prepared from various tissues of adult male Sprague–Dawley rats
were incubated with 4 nM [32P]MRS2500 in the presence or absence
of MRS2179. Specific binding was normalized to protein amounts.
Values are reported as fmol [32P]MRS2500 bound per mg protein.
Data shown are averages of triplicate samples7s.e.m. from a
representative experiment (n¼ 3).
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eliminated interactions of adenosine-30,50-bisphosphate analog
with adenosine receptors, and addition of a methyl group at
the N6 position conferred an increase in P2Y1 receptor-binding
affinity (Boyer et al., 1998). The discovery that interaction
with the P2Y1 receptor was retained in bisphosphate analogs
in which the ribose was replaced by acylic or hetero-
cyclic moieties (Kim et al., 2000; 2001) was extended to the
use of carbocyclic ribose-substituted heterocyclic bispho-
sphate analog constrained in either the Northern or Southern
conformation by fusion of cyclopropane to a pseudosugar
cyclopentane ring (Marquez et al., 1996; Ezzitouni &
Marquez, 1997). These bisphosphate methanocarba analogs
retained affinity for the P2Y1 receptor, and N-methanocarba
derivatives of P2Y1 receptor agonists and antagonists
were more than 100-fold more potent than their corres-
ponding S-isomers (Nandanan et al., 2000; Kim et al., 2002).
Molecular modeling studies of the P2Y1 receptor based on
the structure of rhodopsin confirmed that the Northern
conformation was energetically favored by ligands docked in
the putative P2Y1 receptor ligand recognition site (Nandanan
et al., 2000).
One goal of the development of non-nucleotide P2Y1
receptor antagonists was to reduce interaction of these
molecules with other nucleotide-binding proteins, which
hypothetically should be of value in our secondary goal of
developing a useful radioligand for the P2Y1 receptor. Indeed,
our studies of methanocarba analogs led to the synthesis of
[3H]MRS2279, and the binding of [3H]MRS2279 to mem-
branes prepared from Sf9 insect cells expressing recombinant
human P2Y1 receptors fit the pharmacological properties
of the P2Y1 receptor (Waldo et al., 2002). The [
3H]MRS2279
radioligand-binding assay has allowed efficient screening
of novel ligands for the P2Y1 receptor (Kim et al., 2002;
Waldo et al., 2002) and has been applied to quantify the
P2Y1 receptor during purification to homogeneity (Waldo
& Harden, 2004). Although [3H]MRS2279 proved useful
for quantification of P2Y1 receptors in human platelets
(Waldo et al., 2002), its relatively low specific activity
(89Cimmol1) has limited its use in other tissues in which
the receptor is endogenously expressed. Thus, development
of [32P]MRS2500, which exhibits 10-fold higher affinity and
100-fold higher specific radioactivity than [3H]MRS2279,
represents an important step in ligand development for
the unambiguous study of P2Y1 receptor-binding sites in
mammalian tissues.
Previous work has investigated the tissue distribution of the
rodent P2Y1 receptor using in situ hybridization techniques
(Tokuyama et al., 1995; Janssens et al., 1996; Leon et al., 1996;
Moran-Jimenez & Matute, 2000). These studies suggest a
broad expression pattern for the P2Y1 receptor among
peripheral tissues and in rodent brain. Although in situ
hybridization studies provide important insight into the
relative distribution of this signaling protein, the relationship
of mRNA to expressed functional receptors is unknown and is
not likely to be constant. Antibodies that specifically recognize
P2Y receptors would allow direct immunocytochemical
quantification of receptor protein, but these tools also do
not necessarily identify functional receptor-binding sites.
Moreover, although antibodies against the P2Y1 receptor have
been reported (Fong et al., 2002; Yoshioka et al., 2002; Franke
et al., 2003; Scheibler et al., 2004), evidence for their selectivity
is limited and their general reliability is uncertain.
The results described here illustrate that [32P]MRS2500
is a useful radioligand for quantification of functional
P2Y1 receptor-binding sites across a wide range of mammalian
tissues, and the remarkably high ratio of specific to
nonspecific binding of this high-affinity, high-specific-
activity radioligand allows reliable detection of binding sites
to at least 1 fmolmg1 protein. Application of [32P]MRS2500
revealed a broad expression pattern for the functional
receptor protein among peripheral tissues and rodent
brain. Interestingly, this pattern is similar to that previously
reported for messenger RNA (Tokuyama et al., 1995;
Janssens et al., 1996; Leon et al., 1996; Moran-Jimenez &
Matute, 2000).
Tissue distribution data from our studies and other studies
suggest potentially important physiological consequences of
P2Y1 receptor signaling. The role of the P2Y1 receptor in
ADP-promoted platelet aggregation is now well established
(Gachet, 2001). However, its function remains largely un-
defined in the majority of tissues. Several studies have
investigated the importance of P2Y1 receptor signaling in the
central nervous system. ATP released from nerve terminals
acts as an excitatory neurotransmitter through ionotropic
P2X receptors (Cunha & Ribeiro, 2000). Roles for adenine
nucleotides in other neural processes have been proposed,
and potentially important consequences of signaling involving
the P2Y1 receptor have been suggested. For example, activa-
tion of the P2Y1 receptor inhibits glutamate release, and P2Y1
receptor-mediated inhibition of NMDA receptor-promoted
signaling occurs in prefrontal and parietal cortex (Luthardt
et al., 2003; Rodrigues et al., 2005). Activation of the P2Y1
receptor also has been associated with anxiolysis, astrocyte
protection, and oligodendrocyte proliferation and migration
in rats (Kittner et al., 2003; Agresti et al., 2005; Shinozaki
et al., 2005).
Our work illustrates that [32P]MRS2500 can be utilized to
quantify P2Y1 receptors in very small tissue samples, and the
relatively high affinity and high specific radioactivity of this
radioligand also make it a good candidate for detection of
these receptors using autoradiographic techniques. Previous
studies have claimed autoradiographic detection of the rat
P2Y1 receptor using [a33P]dATP or [35S]dATPaS as radio-
ligands (Simon et al., 1997; Fong et al., 2002), but we have
previously shown that the enormous amount of binding (10–
50 pmolmg1 protein) observed with these radioligands is
nonspecific (Schachter & Harden, 1997). A 33P-labeled
radioligand, [33P]MRS2179, was used previously to quantify
P2Y1 receptors in human platelets (Baurand et al., 2001).
We suspect that [33P]MRS2179 may not be a generally
applicable radioligand since its affinity for the P2Y1 receptor
is 100-fold lower affinity than the affinity of MRS2500.
We have demonstrated here the high selectivity of
[32P]MRS2500 for the P2Y1 receptor, and predict that this
selectivity will allow for a more accurate analysis of brain P2Y1
receptor-binding sites.
The work described here demonstrates the development of
a new molecular tool for quantification of the P2Y1 receptor
with high sensitivity and illustrates that active P2Y1 receptor-
binding sites are broadly distributed across rat tissues
and brain. A reliable means for quantification of the P2Y1
receptor should lead to better understanding of the complex
signaling and physiology associated with this important
signaling protein.
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